FDA approves Investigational New Drug Application for use of Octagam 10% Immune Globulin in severe COVID-19 patients with severe disease progression

The primary objective of randomised, double-blind, placebo-controlled, multicentre study is to determine if high-dose Octagam 10% therapy will slow or stop respiratory deterioration in patients with severe coronavirus disease. Study results are expected by third quarter of 2020.


Biospace Inc.